Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AssigneeThe Regents of the University of California
InventorsJames D. Marks, Ali Razai
Life of this patent
Estimating the term…
Abstract
This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Claims22
An isolated antibody, or antigen-binding fragment thereof, that specifically binds to an epitope of Botulinum neurotoxin type A, wherein the antibody or antigen-binding fragment comprises:
- a) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:165;
- b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:167;
- c) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:203;
- and
- d) VH CDRs comprising:
- i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:91;
- ii) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:93;
- and
- ii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:130;
- or
- i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95;
- ii) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:97;
- and
- ii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:133.
An isolated antibody, or antigen-binding fragment thereof, that specifically binds to an epitope of Botulinum neurotoxin type A, wherein the antibody comprises a full-length light chain comprising:
- a VL CDR1 comprising the amino acid sequence of SEQ ID NO:165;
- a VL CDR2 comprising the amino acid sequence of SEQ ID NO:167;
- a VL CDR3 comprising the amino acid sequence of SEQ ID NO:203;
- a VL framework 1 comprising the amino acid sequence of SEQ ID NO:
- 164;
- a VL framework 2 comprising the amino acid sequence of SEQ ID NO:166;
- a VL framework 3 comprising the amino acid sequence of SEQ ID NO:
- 202;
- and
- a VL framework 4 comprising the amino acid sequence of SEQ ID NO:
- 204.
Dependencies are inferred from the claim text.